NuGen and WaferGen Biosystems are collaborating to develop and market workflows that combine NuGen's sample prep and preamplification technology with WaferGen's SmartChip high-density and –throughput real-time PCR system.
The deal will enable researchers to more easily perform high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace specimens, including formalin-fixed, paraffin-embedded tissue.
WaferGen's fourth-quarter revenues more than tripled and full-year revenues grew more than five-fold, primarily due to sales of its SmartChip products and services; but its net loss mounted as it pumped cash into the commercial launch and marketing of the SmartChip system.
Michael Bates named VP of oncology R&D at Cepheid; IntegenX appoints Dennis Harris as CSO; Timothy Triche joins WaferGen Biosystems' board of directors; Diffinity Genomics appoints John Foskett and Robert Evans to board.
According to the company's earnings statement, MDxHealth's product and service revenues nearly doubled – from €1 million in 2009 to €2 million in 2010 – due to several companion diagnostics deals and biomarker licensing agreements inked with major drug companies.